90 related articles for article (PubMed ID: 29054374)
1. Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early Prostate Cancer.
Langley SEM; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Soares R; Laing R
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):57-64. PubMed ID: 29054374
[TBL] [Abstract][Full Text] [Related]
2. Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.
Langley S; Uribe J; Uribe-Lewis S; Franklin A; Perna C; Horton A; Cunningham M; Higgins D; Deering C; Khaksar S; Laing R
BJU Int; 2020 Mar; 125(3):383-390. PubMed ID: 31705700
[TBL] [Abstract][Full Text] [Related]
3. 4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds.
Langley SE; Laing RW
BJU Int; 2012 Feb; 109 Suppl 1():1-6. PubMed ID: 22239223
[TBL] [Abstract][Full Text] [Related]
4. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
5. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
[TBL] [Abstract][Full Text] [Related]
6. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
[TBL] [Abstract][Full Text] [Related]
7. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
8. Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database.
Mitchell DM; Mandall P; Bottomley D; Hoskin PJ; Logue JP; Ash D; Ostler P; Elliott T; Henry A; Wylie JP
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):738-44. PubMed ID: 18951769
[TBL] [Abstract][Full Text] [Related]
9. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy.
Henry AM; Rodda SL; Mason M; Musunuru H; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):382-6. PubMed ID: 25805312
[TBL] [Abstract][Full Text] [Related]
11. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.
Martell K; Husain S; Taussky D; Angyalfi S; Delouya G; Després P; Beaulieu L; Martin AG; Vigneault E
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):895-903. PubMed ID: 28807532
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
14. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
Ash D; Al-Qaisieh B; Bottomley D; Carey B; Joseph J
Radiother Oncol; 2005 Jun; 75(3):303-6. PubMed ID: 15890423
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
16. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
17. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
18. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
20. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]